Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Zonhon Biopharma Institute Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, indicating separate examination channels for the recorded workload.
EPSTEIN, TODD MATTHEW is the busiest examiner, with 1 pending matter. Each application should be managed through its own examiner-specific review and response plan.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EPSTEIN, TODD MATTHEW | 1 | 60.8% | +43.6% |
| EIX, EMILY FAY | 1 | 45.7% | +76.0% |
| CHASE, CAROL ANN | 1 | 41.9% | +84.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833840 | USE OF KALLIKREIN I OR DERIVATIVE THEREOF IN TREATMENT OF VCI, PSCI OR CSVD | EPSTEIN, TODD MATTHEW | — |
| 18725848 | RECOMBINANT TYPE I ALLERGEN OF ARTEMISIA ANNUA POLLEN, AND PREPARATION METHOD AND USE THEREOF | EIX, EMILY FAY | — |
| 18704066 | ANTI-CD26 ANTIBODIES AND USE THEREOF | CHASE, CAROL ANN | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1653 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833840 | USE OF KALLIKREIN I OR DERIVATIVE THEREOF IN TREATMENT OF VCI, PSCI OR CSVD | EPSTEIN, TODD MATTHEW | 1652 | §103DP | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18725848 | RECOMBINANT TYPE I ALLERGEN OF ARTEMISIA ANNUA POLLEN, AND PREPARATION METHOD AND USE THEREOF | EIX, EMILY FAY | 1653 | §103 | Non-Final OA | — | Pending | Jul 01, 2024 |
| 18704066 | ANTI-CD26 ANTIBODIES AND USE THEREOF | CHASE, CAROL ANN | 1646 | §112DP | Non-Final OA | — | Pending | Apr 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZonhon Biopharma Institute Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Todd Matthew Epstein has the most, with 1 of Zonhon Biopharma Institute Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
